Post-Hoc Analysis Confirms Consistent Clinical Benefit With Olaparib Plus Abiraterone in HRR-Mutated mCRPC
Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.
Stay updated with breaking news from Nonagen Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.
/PRNewswire/ -- Nonagen Bioscience, a cancer diagnostics company, today announced that Timothy "TJ" Johnson has been named Executive Chair of the Nonagen...
The market was worth USD 22.65 billion in 2020 and, with a CAGR of 7.3%, is anticipated to reach a value of USD 45.82 billion by 2030 according to...
/PRNewswire/ -- Being diagnosed with a health condition can often come as a shock but finding out it can recur is a double blow, particularly in the case of...
FinancialNewsMedia.com News Commentary PALM BEACH, FL, June 21, 2022 /PRNewswire/ -- Being diagnosed with a health condition can often come as a shock but finding out it can recur is a